Cognitive research peptides
Semax, Selank, and Dihexa are three structurally distinct compounds studied in preclinical and in vitro models for their neuromodulatory properties. Each represents a different structural class: an ACTH-derived fragment analog, a tuftsin-derived immunomodulatory peptide, and an angiotensin IV analog, respectively.
Each compound is examined in published literature for effects on neurotrophin expression, receptor modulation, and synaptogenic signaling — serving as pharmacological tools to interrogate discrete molecular pathways in the central nervous system. Research interest stems from their selectivity for neurotrophic or inhibitory receptor systems, making them useful probes in animal models and cell culture systems. Published research on these peptides spans neuroprotection, anxiety-related behavior, and synaptic plasticity modeling. All three are supplied for research purposes only.
How Semax modulates BDNF
Semax is a synthetic heptapeptide derived from adrenocorticotropic hormone fragment ACTH(4-7), extended at the C-terminus with a Pro-Gly-Pro sequence. Full sequence: Met-Glu-His-Phe-Pro-Gly-Pro. Published research has characterized Semax's capacity to upregulate brain-derived neurotrophic factor (BDNF) expression in neuronal cell cultures and rodent brain tissue models.
Ashmarin et al. investigated Semax-induced BDNF elevation and downstream TrkB receptor activation in neuronal preparations [PMID: 16445185]. Medvedeva et al. examined gene expression profiles following Semax exposure in brain tissue models, identifying transcriptional changes in multiple neurotrophic pathways [PMID: 18841466]. The peptide's ACTH(4-7) core is thought to interact with melanocortin receptors, with downstream BDNF induction proposed as a secondary consequence. These findings position Semax as a research tool for studying neurotrophin regulation in neuroprotection and cognitive function models. All research applications are for preclinical purposes only.
Selank's anxiolytic mechanism
Selank is a synthetic heptapeptide analog of the endogenous immunomodulatory tetrapeptide tuftsin, extended with Gly-Pro-Lys at the C-terminus. Amino acid sequence: Thr-Lys-Pro-Arg-Pro-Gly-Pro. Molecular formula: C₄₆H₇₃N₁₃O₁₃. Molecular weight: 1046.2 g/mol.
Published research characterizes Selank as an allosteric modulator of GABA-A receptors in neuronal preparations. Kozlovskaya et al. described Selank's effects on GABA-A receptor subunit composition and chloride channel conductance in cell culture models [PMID: 22786332]. Kozlovsky et al. investigated Selank's influence on enkephalin system activity and neurotransmitter expression profiles in brain tissue preparations, identifying interactions with opioid receptor pathways [PMID: 22968004]. Uchakina et al. examined Selank's immunomodulatory properties, including modulation of interleukin expression in immune cell cultures [PMID: 20717095]. In animal models, Selank has demonstrated anxiolytic-like behavioral outcomes in elevated plus maze and open field paradigms. All findings are from preclinical and in vitro research; Selank is supplied for research purposes only.
How Dihexa activates HGF/c-Met signaling
Dihexa (designated PNB-0408) is a synthetic hexapeptide analog of angiotensin IV, developed as a potent agonist of the hepatocyte growth factor (HGF) and its receptor c-Met. Its structure originates from angiotensin IV modifications that enhance binding affinity at the HGF/c-Met receptor complex.
Published research by McCoy et al. demonstrated that Dihexa binds HGF with high affinity and transactivates c-Met signaling cascades in hippocampal preparations, producing synaptogenic effects in neuronal cultures [PMID: 23090578]. Bhatt et al. investigated the synaptogenic properties of Dihexa in rodent models, observing increases in synaptic density markers in hippocampal tissue [PMID: 23548006]. HGF/c-Met signaling activates downstream pathways including PI3K/Akt and MAPK/ERK cascades associated with neuronal survival and synaptic remodeling. Wright et al. characterized the angiotensin IV binding site and its role in cognitive function in rodent models, establishing foundational context for subsequent c-Met-directed analogs including Dihexa [PMID: 20888304]. Published findings identify Dihexa as a research probe for studying synaptogenesis and c-Met-dependent neuroprotection. All applications are for preclinical research only.
Comparison Table
| Compound | Origin | Mechanism | Receptor Target | Molecular Weight | Primary Research Application | Key PMIDs |
|---|---|---|---|---|---|---|
| Semax | ACTH(4-7) analog | BDNF upregulation | TrkB (indirect) | 813 Da | Neuroprotection, cognitive studies | 16445185, 18841466 |
| Selank | Tuftsin analog | GABA-A modulation, enkephalin | GABA-A, opioid receptors | 751 Da | Anxiolytic research, stress response | 22786332, 22968004, 20717095 |
| Dihexa | Angiotensin IV analog | HGF/c-Met agonism | c-Met | 811 Da | Synaptogenesis, cognitive enhancement research | 23090578, 23548006 |
Published research findings
Published literature on Semax focuses on BDNF elevation and neuroprotective gene expression. Ashmarin et al. documented BDNF induction and TrkB activation in neuronal cultures [PMID: 16445185], while Medvedeva et al. identified broad transcriptional changes in neurotrophic factor networks [PMID: 18841466]. For Selank, Kozlovskaya et al. established GABA-A receptor allosteric modulation as a primary mechanism [PMID: 22786332], with Kozlovsky et al. reporting additional effects on enkephalin system activity [PMID: 22968004]. Dihexa research, led by McCoy et al. and Bhatt et al., demonstrates potent HGF/c-Met transactivation and downstream synaptogenic outcomes in hippocampal models [PMID: 23090578] [PMID: 23548006].
Across all three compounds, published findings are derived from cell culture systems and rodent preclinical models. No clinical efficacy claims are supported by this literature in the context of research-grade compound supply. Black Series Lab provides each compound strictly for laboratory investigation.
Frequently Asked Questions
What distinguishes Semax from other ACTH-derived peptides in research?
Semax is distinguished by its specific core sequence ACTH(4-7) — Met-Glu-His-Phe — extended with a C-terminal Pro-Gly-Pro tripeptide that enhances metabolic stability and may influence receptor binding kinetics. Most ACTH fragment analogs target melanocortin receptor subtypes and modulate stress-axis signaling. Semax's profile is distinct in that published research documents secondary induction of BDNF and activation of TrkB-dependent neurotrophic signaling, rather than direct adrenocortical axis effects [PMID: 16445185]. This BDNF-upregulating property is not consistently reported for other ACTH fragment analogs such as ACTH(1-24) or alpha-MSH. Medvedeva et al. further demonstrated that Semax modulates broader gene expression networks related to neuroplasticity [PMID: 18841466]. The Pro-Gly-Pro extension appears central to Semax's differentiated pharmacological profile. All characterization is from preclinical research; Semax is supplied for research purposes only by Black Series Lab.
How is Selank's mechanism different from synthetic benzodiazepines?
Selank and synthetic benzodiazepines both interact with GABA-A receptors, but their binding sites and functional consequences differ in published research models. Classical benzodiazepines bind to the benzodiazepine site at the alpha/gamma subunit interface, producing positive allosteric modulation and increasing chloride conductance. Selank's GABA-A receptor interaction, characterized by Kozlovskaya et al., is described as allosteric modulation with distinct subunit selectivity that differs from benzodiazepine binding profiles [PMID: 22786332]. Selank also engages enkephalin system pathways, an interaction not associated with classical benzodiazepines in published models [PMID: 22968004], and carries tuftsin-derived immunomodulatory properties, including effects on interleukin expression [PMID: 20717095]. These distinct mechanistic features make Selank useful in research designs requiring GABA-A modulation without full benzodiazepine receptor occupancy. Selank is available from Black Series Lab for research purposes only.
What is the significance of HGF/c-Met signaling in Dihexa research?
HGF/c-Met signaling is a receptor tyrosine kinase pathway that regulates neuronal survival, synaptic plasticity, and axonal growth in the central nervous system. Dihexa's research significance lies in its capacity to act as a potent HGF mimetic that transactivates c-Met receptors independently of endogenous HGF ligand. McCoy et al. demonstrated that Dihexa binds HGF with picomolar affinity and activates downstream c-Met phosphorylation in hippocampal tissue preparations [PMID: 23090578]. This signaling pathway activates PI3K/Akt and MAPK/ERK cascades associated with neuronal survival and dendritic spine remodeling. Bhatt et al. reported increased synaptic density markers in hippocampal preparations following Dihexa treatment in rodent models [PMID: 23548006]. Dihexa's potency at this receptor system, reported to exceed that of endogenous HGF in certain assays, makes it a valuable pharmacological probe for synaptic research. All uses of Dihexa are for preclinical research only.
How do researchers measure BDNF changes in Semax studies?
Published Semax research employs several methodologies to measure BDNF changes. ELISA-based protein quantification measures BDNF concentrations in conditioned cell culture media, tissue homogenates, and cerebrospinal fluid fractions. Quantitative PCR measures BDNF mRNA transcript levels in neuronal cell preparations and brain tissue sections, allowing comparison of transcriptional induction across treatment conditions. Immunohistochemistry with anti-BDNF antibodies enables spatial localization of BDNF expression changes in specific brain regions such as hippocampus and cortex. Western blotting confirms mature BDNF protein levels alongside precursor proBDNF in tissue lysates. TrkB receptor phosphorylation assays — phospho-TrkB ELISA and co-immunoprecipitation — confirm downstream receptor activation as characterized by Ashmarin et al. [PMID: 16445185]. Medvedeva et al. also applied gene expression arrays to capture broader transcriptomic responses [PMID: 18841466]. All measurement approaches are applied in preclinical or in vitro contexts.
What research models are used to study Selank's anxiolytic properties?
Published research on Selank's anxiolytic properties primarily uses rodent behavioral paradigms and neurobiological readouts. The elevated plus maze quantifies anxiolytic-like behavior in rats and mice by measuring time spent in open versus closed arms. The open field test assesses locomotor activity and center-zone exploration, which correlate with anxiety-like states in rodent models. Published studies by Kozlovskaya et al. and Kozlovsky et al. employed neurochemical endpoints including GABA-A receptor binding assays and enkephalin peptide quantification to establish mechanistic correlates of behavioral outcomes [PMID: 22786332] [PMID: 22968004]. Stress-induced hyperthermia models assess anxiolytic effects at the physiological level. In vitro models complement behavioral work by enabling direct receptor binding measurements in neuronal cell preparations. Uchakina et al. used immune cell culture systems to characterize the immunomodulatory dimension of Selank's activity [PMID: 20717095]. All models are preclinical; Selank is supplied by Black Series Lab for research purposes only.
All compounds listed are for research purposes only. Black Series Lab provides research-grade peptides intended for laboratory and preclinical research. Not for human or veterinary use.